biote Corp. (NASDAQ:BTMD – Get Free Report) major shareholder Guines Llc bought 43,378 shares of biote stock in a transaction that occurred on Monday, April 7th. The stock was bought at an average price of $3.15 per share, with a total value of $136,640.70. Following the purchase, the insider now owns 4,107,987 shares of the company’s stock, valued at $12,940,159.05. This trade represents a 1.07 % increase in their position. The acquisition was disclosed in a legal filing with the SEC, which is available through this hyperlink. Large shareholders that own more than 10% of a company’s shares are required to disclose their transactions with the SEC.
Guines Llc also recently made the following trade(s):
- On Thursday, April 3rd, Guines Llc purchased 7,321 shares of biote stock. The stock was purchased at an average cost of $3.24 per share, with a total value of $23,720.04.
- On Monday, March 31st, Guines Llc acquired 106,000 shares of biote stock. The shares were purchased at an average cost of $3.32 per share, for a total transaction of $351,920.00.
- On Monday, March 17th, Guines Llc bought 100 shares of biote stock. The stock was purchased at an average price of $3.74 per share, with a total value of $374.00.
- On Thursday, March 13th, Guines Llc purchased 750,000 shares of biote stock. The stock was acquired at an average cost of $3.22 per share, for a total transaction of $2,415,000.00.
biote Stock Performance
BTMD stock opened at $3.25 on Wednesday. biote Corp. has a 1-year low of $3.04 and a 1-year high of $8.44. The business’s 50 day moving average is $4.20 and its 200-day moving average is $5.25. The firm has a market cap of $177.81 million, a P/E ratio of 12.50 and a beta of 1.17.
Institutional Trading of biote
Wall Street Analyst Weigh In
Separately, Craig Hallum decreased their target price on shares of biote from $12.00 to $8.00 and set a “buy” rating on the stock in a research report on Thursday, March 13th.
View Our Latest Analysis on BTMD
biote Company Profile
biote Corp. operates in practice-building business within the hormone optimization space. It trains physicians and nurse practitioners in hormone optimization using bioidentical hormone replacement pellet therapy in men and women experiencing hormonal imbalance. The company offers Biote Method, a comprehensive end-to-end practice building platform that provides Biote-certified practitioners with the components developed for practitioners in the hormone optimization space comprising Biote Method education, training, and certification services; practice management software that allows Biote-certified practitioners to order, track, and manage hormone optimization product inventory and other administrative requirements; inventory management software to monitor pellet inventory; and information regarding available hormone replacement therapy products, as well as digital and point-of-care marketing support.
See Also
- Five stocks we like better than biote
- 3 REITs to Buy and Hold for the Long Term
- Tariff-Proof Stocks: 3 Big Bargains With Huge Upside Potential
- Stock Market Holidays 2022-2025 – Here’s When the NYSE and NASDAQ Will be Closed
- Qualcomm Breaks Down But RSI Signals It’s Severely Oversold
- With Risk Tolerance, One Size Does Not Fit All
- Tesla’s #1 Bull Cuts Target But Says It’s Still a Buy
Receive News & Ratings for biote Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for biote and related companies with MarketBeat.com's FREE daily email newsletter.